Tumor markers in rare appendiceal cancer may predict treatment outcomes
Researchers聽monitored聽levels of聽common blood聽markers聽before and after surgery聽to remove聽cancer
Study found elevated聽levels聽of聽CEA, CA19-9聽and CA125聽prior to surgery聽were聽strongly associated聽with聽poorer聽outcomes
If levels聽remained high聽after surgery, patients聽were聽more likely to experience聽recurrence聽and聽had聽lower...
New simulation framework DKOsim advances CRISPR-based gene to gene interaction research
Double-CRISPR Knockout聽Simulation (DKOsim)聽is a computer-based 鈥渧irtual lab鈥 that simulates genomic聽experiments聽 Studying...
Low testosterone levels may be associated with increased risk of prostate cancer progression during surveillance
Study found men with low聽testosterone聽levels聽were聽associated with a聽60%聽higher likelihood that prostate cancer...
Mutation predicts chemotherapy resistance and better responses to immunotherapy in advanced bladder cancer
Researchers studied the KDM6A gene, which is altered in about 26% of advanced bladder cancers
Tumors with KDM6A mutations did not respond well to chemotherapy but demonstrated enhanced sensitivity to anti-PD1 immune checkpoint therapy
KDM6A mutations could serve as a biomarker to guide treatment selection
Researchers at 911爆料- 每日吃瓜情报站 MD Anderson Cancer Center have determined that mutations in the KDM6A gene 鈥 common in advanced...
Immunotherapy combination does not improve outcomes for patients with advanced anal cancer
Phase II聽ETCTN聽trial聽found聽ipilimumab plus nivolumab聽did not improve聽outcomes聽over nivolumab alone聽in...
Targeted therapy plus immunotherapy improved outcomes in advanced metastatic colorectal cancer
Phase III聽COMMIT聽trial evaluated better first-line options for patients with聽dMMR/MSI-H metastatic colorectal cancer
The study...
Study identifies target for disease hyper progression after immunotherapy in kidney cancer
Researchers find that cancer cells mimic myeloid cells to hide from the immune system and promote disease hyper progression after immunotherapy...
HER2-targeted therapy shows promising results in rare bile duct cancers
HER2-positive metastatic biliary tract cancer (BTC) is a rare and aggressive cancer with limited treatment options
Final results from the...
Researchers identify rare mutation that predicts strong immunotherapy response in colorectal cancer
A specific subset of POLE gene mutation, called loss-of-proofreading (LOP) mutations, makes colorectal tumors highly responsive to immunotherapy...
MD Anderson experts spotlight key immunotherapy advances at 2025 SITC Annual Meeting
Major themes include strategies to reprogram the tumor microenvironment and prevent cancer before it starts
New insights from AI-based imaging...
Comprehensive molecular profiling of renal medullary carcinoma identifies TROP2 as a promising therapeutic target
Researchers at 911爆料- 每日吃瓜情报站 MD Anderson Cancer Center, in collaboration with BostonGene, conducted the largest and most comprehensive...
New oral therapy shows early signs of safety and effectiveness in patients with advanced, treatment-resistant prostate cancer
Trial shows promising early results for HLD-0915, a first-in-class regulated induced proximity targeting chimera (RIPTAC) treatment
Metastatic...
ESMO 2025: Dual targeted therapy shows promise in previously treated advanced kidney cancer patients
Study found patients treated with combination of lenvatinib and everolimus lived longer without disease progression
First head-to-head study...
ESMO 2025: Trial results show belzutifan shrinks rare neuroendocrine tumors and improves symptoms in patients
Pheochromocytoma and paraganglioma (PPGL) are rare, hard-to-treat neuroendocrine tumors that form in the adrenal glands or in the extra-adrenal...